Matinas Biopharma (MTNB) Stock Forecast & Price Target

$0.60 -0.03 (-5.39%)

(As of 12:11 PM ET)

Matinas Biopharma - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 2 Analyst Ratings

Sell
0

Hold
2

Buy
0

Based on 2 Wall Street analysts who have issued ratings for Matinas Biopharma in the last 12 months, the stock has a consensus rating of "Hold." Out of the 2 analysts, 2 have given a hold rating for MTNB.

Consensus Price Target

N/A

Get the Latest News and Ratings for MTNB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Matinas Biopharma and its competitors.

MTNB Analyst Ratings Over Time

Type	Current Forecast 11/16/23 to 11/15/24	1 Month Ago 10/17/23 to 10/16/24	3 Months Ago 8/18/23 to 8/17/24	1 Year Ago 11/16/22 to 11/16/23
Strong Buy	0 Strong Buy rating(s)	N/A	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	0 Buy rating(s)	N/A	1 Buy rating(s)	2 Buy rating(s)
Hold	2 Hold rating(s)	N/A	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	N/A	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	N/A	N/A	$3.00	$3.00
Forecasted Upside	N/A	N/A	1,515.51% Upside	733.33% Upside
Consensus Rating	Hold	N/A	Buy	Buy

Has Trump Finally Gone Too Far? (Ad)

Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

MTNB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MTNB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Matinas Biopharma Stock vs. The Competition

Type	Matinas Biopharma	Medical Companies	S&P 500
Consensus Rating Score	2.00	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	N/A	26,221.89% Upside	8.88% Upside
News Sentiment Rating	Positive News See Recent MTNB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/1/2024	Alliance Global Partners 1 of 5 stars	J. Molloy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/31/2024	Maxim Group 4 of 5 stars	J. Mccarthy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/11/2023	BTIG Research 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$3.00	+368.01%
1/31/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$3.00	+420.37%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 12:34 PM ET.

MTNB Forecast - Frequently Asked Questions

: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas Biopharma in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MTNB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MTNB, but not buy additional shares or sell existing shares.
: According to analysts, Matinas Biopharma's stock has a predicted downside of -100.00% based on their 12-month stock forecasts.
: Over the previous 90 days, Matinas Biopharma's stock had 2 downgrades by analysts.
: Matinas Biopharma has been rated by research analysts at Alliance Global Partners, and Maxim Group in the past 90 days.
: Analysts like Matinas Biopharma less than other "medical" companies. The consensus rating for Matinas Biopharma is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how MTNB compares to other companies.

Stock Forecasts and Research Tools

Today's Ratings

Top Rated Stocks

More Ratings Tools

The next assassination attempt won’t be on Trump (Ad)

President Trump is soon to be back in the White House. Unity has been restored to the U.S. But if you watched the President’s 25-minute victory speech, you probably noticed he spent nearly four minutes speaking about one very controversial person.

I share with you in this special investigative documentary.

This page (NYSE:MTNB) was last updated on 11/15/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Matinas Biopharma (MTNB) Stock Forecast & Price Target